# The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers

> **NCT02982798** · PHASE1 · COMPLETED · sponsor: **Jeil Pharmaceutical Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Diabetes
- Hyperlipidemia

## Interventions

- **DRUG:** Metformin + Rosuvastatin
- **DRUG:** JLP-1310

## Key facts

- **NCT ID:** NCT02982798
- **Lead sponsor:** Jeil Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-06
- **Primary completion:** 2017-08-30
- **Final completion:** 2018-01-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02982798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02982798, "The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02982798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*